A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 STUDY EVALUATING THE SAFETY AND EFFICACY OF ORAL GKT137831 IN PATIENTS WITH TYPE 2 DIABETES AND ALBUMINURIA
- Registry ID
- GSN000200
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- GENKYOTEX INNOVATION SAS
- Start date
- 2014-04-07
- Last update
- 2013-09-24
Conditions
- ALBUMINURIA
- TYPE 2 DIABETES
Related clinical trials
- A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP PHASE III STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ELECOGLIPRON COMPARED WITH ORAL SEMAGLUTIDE IN ADULTS WITH TYPE 2 DIABETES MELLITUS (ELUMINATE-2)
- A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-WEEKLY RO7795068 ADMINISTERED TO PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES
- EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY-BIASED, ULTRA LONG-ACTING GLP-1RA, IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES: A PHASE 3, MULTI-CENTER RANDOMIZED, PLACEBO-CONTROLLED TRIAL (VESPER-5)
- EFFICACY AND SAFETY OF CAGRILINTIDE FOR WEIGHT MANAGEMENT IN PARTICIPANTS
WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES (RENEW 2)
- A PHASE I/II, RANDOMISED, SINGLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-ASCENDING-DOSE
STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF
AZD9550 MONOTHERAPY AND CO-ADMINISTRATION OF AZD9550 AND AZD6234 IN PARTICIPANTS
LIVING WITH OBESITY AND OVERWEIGHT WITH OR WITHOUT TYPE 2 DIABETES MELLITUS
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTI-CENTER PHASE 2 STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ONCE-WEEKLY CT-388 ADMINISTERED SUBCUTANEOUSLY FOR 48 WEEKS TO PARTICIPANTS WHO ARE OVERWEIGHT OR OBESE WITH TYPE 2 DIABETES MELLITUS
View on source registry